Subscribe Sign In

Why register?

Home
News
Events
- Find an event
- Live event coverage
Deep Dive
Sales and marketing
Digital
Market Access
Oncology
Patients
R&D
Spotlight On
- Frontiers Health 2022
- The Future of Generics
Advertise

Search

Search

Close

Trending

An inside peek into pharma marketing at PM Society learning event – part i

SABCS: AZ’s oral SERD data may “relaunch enthusiasm” for class

SABCS: New ADC from AZ and Daiichi shows promise in breast cancer

PharmStars digital health accelerator names its second class of 2022

Autolus announces primary endpoint met in FELIX trial, prices public offering

navitoclax

AbbVieHQ

News/ News/ News/ Oncology/ R&D

AACR: AbbVie says mid-stage trial backs navitoclax in myelofibrosis

Phil Taylor AbbVie, Haematology, myelofibrosis, navitoclax, novel targeted cancer treatments, Oncology, Venclexta 0 Comment

AbbVie’s BCL-2 inhibitor navitoclax has reported phase 2 results in a trial involving rare and hard-to-treat blood cancer

X

AACR: AbbVie says mid-stage trial backs navitoclax in myelofibrosis

https://pharmaphorum.com/news/aacr-abbvie-says-mid-stage-trial-backs-navitoclax-in-myelofibrosis/

Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox

Featured content

How to improve payer engagement with tailored value communication

How to improve payer engagement with tailored value communication

How will NICE fare in a post-Brexit world?

How will NICE fare in a post-Brexit world?

Events

Frontiers Health Steering Committee spotlight – Monique Levy

Frontiers Health Steering Committee spotlight – Monique Levy

MAPS 2018 EMEA Annual Meeting

MAPS 2018 EMEA Annual Meeting

Cell & Gene Therapy 2018

Cell & Gene Therapy 2018

Most popular

Most Viewed

GSK trumpets Jemperli vs Keytruda data in first-line NSCLC
Novartis builds case for iptacopan as oral rival to PNH injectables
US court throws out lawsuits alleging Zantac caused cancer
Evidence standard drawn up for digital therapeutics
RSV vaccine race in balance as FDA sets May date for Pfizer decision

Tweets from @pharmaphorum

Tweets by @pharmaphorum

Advertise

Contribute
Work for pharmaphorum

About us
Contact us
Privacy policy
Terms & conditions
Cookie Policy

The rights of trade mark owners are acknowledged. pharmaphorum media limited

Website and content copyright © 2009-, pharmaphorum media limited or its licensors; all rights reserved.

© 2022

Powered by WordPress • Themify WordPress Themes

Login

Username or Email Address

Password

Remember Me

Lost your password?

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com